|
127 Companies |
|
139 Products |
|
139 Products |
|
89 Mechanisms of Action |
|
9 Trials |
|
1220 News |
|
| «12...13141516171819202122232425» |
- Biomarker: Laparoscopic Total Fundoplication for Duodenogastroesophageal Reflux (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=188, Completed, Sponsor: University of Turin, Italy
- Trial initiation date: Screening for Gastric Cancer in High-risk Population (clinicaltrials.gov) - Dec 1, 2012
P=N/A, N=450, Recruiting, Sponsor: Rabin Medical Center
Initiation date: Apr 2009 --> Oct 2009
- Enrollment open: Screening for Gastric Cancer in High-risk Population (clinicaltrials.gov) - Dec 1, 2012
P=N/A, N=450, Recruiting, Sponsor: Rabin Medical Center
Initiation date: Apr 2009 --> Oct 2009 Not yet recruiting --> Recruiting
- Trial completion: Fecal Screening Assay for Taiwanese Population (clinicaltrials.gov) - Nov 29, 2012
P=N/A, N=3172, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- | CUDC-101 / Curis
Trial completion, Metastases: A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors (clinicaltrials.gov) - Nov 29, 2012
P1, N=40, Completed, Sponsor: Curis, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Herceptin (trastuzumab) / Roche
New P2 trial: A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer (clinicaltrials.gov) - Nov 27, 2012
P2, N=30, Completed, Sponsor: National Cancer Centre, Singapore
- Trial withdrawal: The Use of Domperidone for Gastroparesis (clinicaltrials.gov) - Nov 20, 2012
P3, N=0, Withdrawn, Sponsor: Allegiance Health
Active, not recruiting --> Completed Recruiting --> Withdrawn
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial initiation date, Surgery, Metastases: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - Nov 20, 2012
P=N/A, N=11, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Withdrawn Initiation date: Jul 2012 --> Nov 2012
- Enrollment change: The Use of Domperidone for Gastroparesis (clinicaltrials.gov) - Nov 20, 2012
P3, N=0, Withdrawn, Sponsor: Allegiance Health
Initiation date: Jul 2012 --> Nov 2012 N=30 --> 0
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment open, Surgery, Metastases: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - Nov 20, 2012
P=N/A, N=11, Recruiting, Sponsor: City of Hope Medical Center
N=30 --> 0 Not yet recruiting --> Recruiting
- gemcitabine / Generic mfg.
Trial completion: Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer (clinicaltrials.gov) - Nov 20, 2012
P1, N=16, Completed, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||| rilotumumab (AMG 102) / Amgen
Enrollment open, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Nov 18, 2012
P3, N=450, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche
Enrollment change: A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer (clinicaltrials.gov) - Nov 14, 2012
P2, N=36, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=45 --> 36
- | Herceptin (trastuzumab) / Roche
Enrollment closed: A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer (clinicaltrials.gov) - Nov 14, 2012
P2, N=36, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=45 --> 36 Recruiting --> Active, not recruiting
- ||||| Enrollment closed: FDTT: Functional Dyspepsia Treatment Trial (clinicaltrials.gov) - Nov 14, 2012
P2/3, N=400, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| lucitanib (E 3810) / Clovis, Servier
Trial completion: A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204) (clinicaltrials.gov) - Nov 14, 2012
P2, N=338, Completed, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Nov 14, 2012
P2, N=39, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Trial termination, Surgery, Metastases: Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers (clinicaltrials.gov) - Nov 8, 2012
P2, N=8, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Completed Active, not recruiting --> Terminated; Due to slow accrual
- | Trial completion: Endoscopic Submucosal Dissection Registry (clinicaltrials.gov) - Nov 6, 2012
P=N/A, N=17, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Terminated; Due to slow accrual Active, not recruiting --> Completed
- |||||| onartuzumab (RG3638) / Roche
Enrollment open, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Nov 4, 2012
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | simvastatin / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Metastases: Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients (clinicaltrials.gov) - Nov 3, 2012
P3, N=244, Active, not recruiting, Sponsor: Samsung Medical Center
Not yet recruiting --> Recruiting N=332 --> 244
- escitalopram / Generic mfg.
Trial termination, Metastases: Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer (clinicaltrials.gov) - Nov 1, 2012
P3, N=24, Terminated, Sponsor: Massachusetts General Hospital
N=332 --> 244 Active, not recruiting --> Terminated; DSMB stopped study because placebo arm had more adverse events
- escitalopram / Generic mfg.
Enrollment change, Metastases: Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer (clinicaltrials.gov) - Nov 1, 2012
P3, N=24, Terminated, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Terminated; DSMB stopped study because placebo arm had more adverse events N=220 --> 24
- ||||| Enrollment change: Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis (clinicaltrials.gov) - Oct 31, 2012
P3, N=58, Completed, Sponsor: University of Mississippi Medical Center
N=220 --> 24 N=40 --> 58
- ||||||| Trial completion: Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis (clinicaltrials.gov) - Oct 31, 2012
P3, N=58, Completed, Sponsor: University of Mississippi Medical Center
N=40 --> 58 Active, not recruiting --> Completed
- | velusetrag (TD-5108) / Innoviva
New P2 trial: Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis (clinicaltrials.gov) - Oct 30, 2012
P2, N=32, Active, not recruiting, Sponsor: Theravance, Inc.
- | Vectibix (panitumumab) / Amgen
New P1/2 trial: Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Oct 28, 2012
P1/2, N=108, Recruiting, Sponsor: Hellenic Oncology Research Group
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, New P2 trial, Metastases: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. (clinicaltrials.gov) - Oct 24, 2012
P2, N=127, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment change: Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=55, Completed, Sponsor: Henry C. Lin, MD
Active, not recruiting --> Completed N=120 --> 55
- Trial completion: ADCI001: Prognosis of Signet Ring Cells in Upper Digestive Neoplasms (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=2500, Completed, Sponsor: University Hospital, Lille
N=120 --> 55 Recruiting --> Completed
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion: Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=55, Completed, Sponsor: Henry C. Lin, MD
Recruiting --> Completed Recruiting --> Completed
- | Inlyta (axitinib) / Pfizer
Trial completion, Combination therapy, Metastases: Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Oct 17, 2012
P1, N=22, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Antiangiogenic Factors in Gastric Cancer (clinicaltrials.gov) - Oct 15, 2012
P=N/A, N=240, Completed, Sponsor: National Cancer Center, Korea
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change: Supplementary Angiographic Embolization for Peptic Ulcer Bleeding (clinicaltrials.gov) - Oct 10, 2012
P=N/A, N=105, Completed, Sponsor: Odense University Hospital
Recruiting --> Completed N=200 --> 105
- MK-2206 / Merck (MSD), Herceptin (trastuzumab) / Roche
New P1 trial: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 10, 2012
P1, N=60, Terminated, Sponsor: National Cancer Institute (NCI)
- Trial completion: Supplementary Angiographic Embolization for Peptic Ulcer Bleeding (clinicaltrials.gov) - Oct 10, 2012
P=N/A, N=105, Completed, Sponsor: Odense University Hospital
N=200 --> 105 Recruiting --> Completed
- lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open, Metastases: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 9, 2012
P1, N=15, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed Active, not recruiting --> Recruiting
- AZD1480 / AstraZeneca
Enrollment change, Metastases, Biopsy: A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. (clinicaltrials.gov) - Oct 8, 2012
P1, N=47, Terminated, Sponsor: AstraZeneca
Active, not recruiting --> Recruiting N=60 --> 47
- clarithromycin / Generic mfg.
Enrollment change: Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori (clinicaltrials.gov) - Oct 6, 2012
P4, N=180, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
N=60 --> 47 N=100 --> 180
- |||||||||| rilotumumab (AMG 102) / Amgen
New P3 trial, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Sep 30, 2012
P3, N=450, Recruiting, Sponsor: Amgen
- ||| Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Metastases: A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer (clinicaltrials.gov) - Sep 27, 2012
P2, N=166, Active, not recruiting, Sponsor: Eli Lilly and Company
N=100 --> 180 Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., cisplatin / Generic mfg.
Trial termination, Surgery, Metastases: Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=144, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; low accrual
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Trial completion, Metastases: Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Sep 17, 2012
P2, N=33, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- Trial withdrawal: Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription Associated to Non-steroidal Anti-inflammatory Drugs (NSAIDs) (clinicaltrials.gov) - Sep 12, 2012
P=N/A, N=0, Withdrawn, Sponsor: Servicio Canario de Salud
Active, not recruiting --> Completed Suspended --> Withdrawn
- Trial withdrawal: Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer (clinicaltrials.gov) - Sep 12, 2012
P1, N=0, Withdrawn, Sponsor: University of California, San Francisco
Suspended --> Withdrawn Completed --> Withdrawn
- Enrollment change: Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription Associated to Non-steroidal Anti-inflammatory Drugs (NSAIDs) (clinicaltrials.gov) - Sep 12, 2012
P=N/A, N=0, Withdrawn, Sponsor: Servicio Canario de Salud
Completed --> Withdrawn N=168 --> 0
- Trial termination: Domperidone for Relief of Gastrointestinal Disorders (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=42, Terminated, Sponsor: Carle Physician Group
N=168 --> 0 Active, not recruiting --> Terminated; PI withdrew due to increased responsibilities in clinical department.
- Enrollment change: Domperidone for Relief of Gastrointestinal Disorders (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=42, Terminated, Sponsor: Carle Physician Group
Active, not recruiting --> Terminated; PI withdrew due to increased responsibilities in clinical department. N=80 --> 42
- || cisplatin / Generic mfg.
New P2/3 trial: HIPECStomach: Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer (clinicaltrials.gov) - Sep 10, 2012
P2/3, N=60, Recruiting, Sponsor: PD Dr. Derek Zieker
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Monotherapy, Metastases: ARQ 197-004: Study of ARQ 197 Monotherapy (clinicaltrials.gov) - Sep 5, 2012
P2, N=0, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
N=80 --> 42 Active, not recruiting --> Completed